UCEA - Family Office Group’s Post

🎤 InnoPath Therapeutics presenting at Biotech Showcase™ in our #SeedShowcase specialized track! Peter Trepp, CEO of Innopath Therapeutics, will present how the company aims to improve the lives of the tens of millions of people with actinic keratosis and non-melanoma skin cancer each year. Based in Sherman Oaks, California, the company’s therapeutic focus areas include oncology and dermatology. 🗓️ Register to attend and learn more: https://lnkd.in/eVfUegPD Are you a pioneering biotech startup looking to gain a competitive edge in today’s challenging landscape? Seed Showcase highlights emerging companies with under $2M in funding that are developing innovative therapeutic products. Taking place at Biotech Showcase, Seed Showcase is happening January 13–15, 2025, in San Francisco, CA, with virtual sessions from January 16–17 on the partneringONE platform. This conference offers an unparalleled opportunity to showcase your organization and connect with strategic partners. 📝 Apply to present your innovations: https://lnkd.in/ekZuFZ5p 🌁 What to expect at Biotech Showcase: https://lnkd.in/eRq7FKg4 #BiotechShowcase #DemyColton #EBDGroup #LifeSciences #Oncology #Dermatology #Innovation #Investors #Partnering #InnoPathTherapeutics EBD Group Demy-Colton

AMLo Biosciences are excited to read in Precision Oncology that the University of Michigan have discovered a prognostic #biomarker that could help to identify renal cancers at high risk of recurrence. https://bit.ly/3LlBEhi The lead author notes that, “We need biomarkers to identify and better treat those who need to be treated and avoid treatment in those that do not need to be treated.” Similarly, our biomarker technology, #AMBLor, can accurately identify early-stage #melanomas at low-risk of progression using the skin samples taken at the staging biopsy. This additional prognostic information can risk-stratify melanomas helping clinical decision makers with personalised disease management and follow-up. www.amlo-biosciences.com   AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. The AMBRA1 and loricrin test is available in the UK as a UKAS accredited LDT #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers  

🧪🔬 Did you know that trial durations for most disease areas have remained stable over the last decade? 📊 However, there have been some interesting trends, especially in oncology. 🩺💉 🕑 Phase I trials are typically short, except for oncology, rare diseases, vaccines, and dermatology, which often last less than a year. 📅 📉 Total oncology trial duration has actually decreased by an average of 1% per year through 2018, with Phase II trials seeing the most significant reductions. 💪 🌟 Despite these trends, oncology and rare diseases still have the longest timelines overall. 🕰️ This is likely due to challenges in patient recruitment and the need for extended observation periods. 🧠 💡 How can you leverage these insights in your clinical trial planning? By using Exigyn's clinical trial budgeting tool, you can incorporate these trends into your financial projections, ensuring that your budget aligns with the unique demands of oncology and rare disease trials. 💼 #ClinicalTrials #Oncology #RareDiseases #Vaccines #Dermatology #PhaseTrials #PatientRecruitment #TrialDuration #ClinicalResearch #Budgeting #Exigyn #Healthcare #Research #Innovation #Science #Pharmaceuticals #DrugDevelopment #DataAnalysis #Insights

The coagulation cascade's "holy grail" has long been separating efficacy from bleeding risk. After Bayer's asundexian failure and Bristol Myers Squibb / Johnson & Johnson's milvexian setback, Regeneron's domain-specific Factor XI antibodies reveal why precision matters... What makes this approach particularly clever is how it works: - Traditional Factor Xa inhibitors block a single point in the cascade - REGN7508 targets Factor XI's catalytic domain, maximizing anticoagulation while preserving hemostasis - REGN9933 hits the A2 domain instead, offering a different risk profile - The single-dose administration (versus daily pills) suggests exceptional target engagement With Phase 2 data showing REGN7508 beating enoxaparin (7% vs 21% VTE) and matching Eliquis in knee replacement surgery, Regeneron is taking a fundamentally different approach to the $20B anticoagulation market. But the real innovation isn't in the numbers - it's in the mechanism. This isn't just about better anticoagulation - it's about understanding coagulation biology at a deeper level. The failing of previous Factor XI approaches wasn't in the target choice, but in understanding how different domains control different aspects of the cascade. Could domain-specific targeting finally solve the decades-old challenge of separating antithrombotic efficacy from bleeding risk? #DrugDevelopment #Hematology #TherapeuticAntibodies #PrecisionMedicine #ClinicalTrials ------------------- Hi, I'm James - I post about all things immunology. I am Vice President of Sales at ichorbio (www.ichor.bio), a bulk manufacturer of in vivo antibodies and research biosimilars. If you like my content please reshare with your network and follow me to see more!

𝗗𝗲𝗿𝗺-𝗕𝗶𝗼𝗺𝗲 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝘀 𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗼𝗿 𝗧𝗼𝗽𝗶𝗰𝗮𝗹 𝗦𝗸𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 Derm-Biome Pharmaceuticals, a Vancouver-based company, is developing a topical treatment that shows promise in both preventing and treating skin cancer. Preclinical trials using mice exposed to UVB radiation suggest the treatment can: ▪ Reduce precancerous lesions ▪ Block tumor progression ▪ Have minimal side effects (unlike some current options) ▪ This could be a game-changer for patients with high risk of skin cancer or those with actinic keratosis (AK), a common precancerous condition. Derm-Biome's findings suggest their topical formulation has the potential to be a highly effective and well-tolerated option for both the prevention and treatment of squamous cell carcinoma. They are currently seeking seed funding to advance development and initiate IND-enabling studies later this year. This research holds significant promise for improving skin cancer outcomes and patient quality of life 🏥 Contact  BIOBOSTON CONSULTING today or visit our  website to learn more about how we can support your organization. #SkinCancer #Dermatology #ClinicalTrials #DermBiomePharmaceuticals

Triveni Bio has successfully secured $115 million in Series B financing to advance their innovative pipeline targeting immunological and inflammatory (I&I) disorders. Key points: 1. Funding led by Goldman Sachs Alternatives, with participation from Fidelity Management & Research Company, Deep Track Capital, and existing investors. 2. Primary focus: Advancing TRIV-573, a second-generation anti-kallikrein 5/7+IL-13 bispecific antibody, through clinical proof-of-concept. 3. Lead candidate TRIV-509 (monoclonal antibody inhibitor targeting KLK 5/7) on track for IND submission in Q1 2025. 4. Expansion of data science platform, emphasizing precision dermatology. 5. Development of trypsin 1 and 2 inhibitor for hereditary pancreatitis, addressing an unmet medical need. Questions for discussion: - How might the combination of KLK 5/7 inhibition with IL-13 targeting in TRIV-573 potentially overcome current limitations in treating atopic dermatitis? - What are your thoughts on the increasing role of data science in precision dermatology, and how might this impact future therapeutic developments? - Given the lack of approved treatments for hereditary pancreatitis, what challenges and opportunities do you foresee in Triveni's pursuit of a trypsin 1 and 2 inhibitor for this indication? #BiotechInnovation #ImmunologyResearch #PrecisionMedicine #SeriesBFunding

The US annual direct healthcare expenditure for individuals with melanoma was around $13.56 billion between 2011 to 2020. This national study found that the marginal total expenditures in the #melanoma cohort were $2,844.75 greater compared with the non-melanoma skin cancer cohort. The majority of the costs relate to doctor visits and hospital stays. bit.ly/41eDt98 Here at AMLo Biosciences we understand the financial burden of melanoma management. #AMBLor our prognostic test, enables risk stratification of individual melanomas leading to more appropriate follow-up for patients at low risk of disease progression and consequently offers the potential for cost savings as well as easing patient anxiety and supporting personalised management. amlo-biosciences.com   AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor ® has received its UKCA mark in the UK. #dermatology #dermatopathology #histopathology #oncology #skincancer #cancerresearch #biomarkers 

Ready to #sunbath? Biotech industry has introduced groundbreaking #innovations towards new treatment for the most common #pathologies, especially when it comes to specific realities in the field of #oncology and #immunology . #Melanoma, among the others, is taking off in terms of new #treatments and Europe is going to rapresent one of the major opportunities for saving millions of #patients every year. Wanna deepen your knowledge about it? Do not miss my new article! #pharmaceutical #biotech #marketing #strategy #melanoma #cancer #skin #dermatology #drugs #pharma https://lnkd.in/duwS5qW8

#AAO2024: Patients with substantial vision loss due to advanced retinitis pigmentosa (RP) achieved meaningfully improved visual acuity after 1 intravitreal injection of an optogenetic therapy, multi-characteristic opsin (MCO-010, Nanoscope Therapeutics, Inc), according to data from the RESTORE trial (ClinicalTrials .gov Identifier: NCT04945772). Phase 2b/3 topline results were presented at the annual meeting of American Academy of Ophthalmology (AAO) in Chicago, October 18 to 21, 2024. Presented by Allen Ho, MD, FACS, FASRS. Read more: https://bit.ly/4hfiFUl #VisionLoss #RetinitisPigmentosa #VisualAcuity #IntravitrealInjection #OptogeneticTherapy #MultiCharacteristicOpsin #MCO010 #RESTORE #Ophthalmology #EyeHealth #EyeCare #NCT04945772

What are your thoughts on Triveni Bio's approach to precision dermatology and their work on hereditary pancreatitis? Check out our post below for more details and join the discussion 😊